Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
Completed · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Sporadic Inclusion Body Myositis
In brief
This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM).
Key facts
- Study ID
- NCT01925209
- Run by
- Novartis Pharmaceuticals
- People needed
- 251
- Starts
- 2013-09-26
- Expected to finish
- 2016-01-06
- Last updated by the study team
- 2017-08-11
Who can join
Age: 36 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Phoenix, Arizona, United States
- Novartis Investigative Site — Orange, California, United States
- Novartis Investigative Site — Sacramento, California, United States
- Novartis Investigative Site — Miami, Florida, United States
- Novartis Investigative Site — Kansas City, Kansas, United States
- Novartis Investigative Site — Baltimore, Maryland, United States
- Novartis Investigative Site — Boston, Massachusetts, United States
- Novartis Investigative Site — Boston, Massachusetts, United States
- Novartis Investigative Site — Columbus, Ohio, United States
- Novartis Investigative Site — Portland, Oregon, United States
- Novartis Investigative Site — Dallas, Texas, United States
- Novartis Investigative Site — Houston, Texas, United States
- Novartis Investigative Site — St Leonards, New South Wales, Australia
- Novartis Investigative Site — Cauldfield, Victoria, Australia
- Novartis Investigative Site — Nedlands, Western Australia, Australia
- Novartis Investigative Site — Brussels, Belgium
- Novartis Investigative Site — Edegem, Belgium
- Novartis Investigative Site — Ghent, Belgium
- Novartis Investigative Site — Copenhagen, Denmark
- Novartis Investigative Site — Paris, France
- Novartis Investigative Site — Brescia, BS, Italy
- Novartis Investigative Site — Rome, Lazio, Italy
- Novartis Investigative Site — Messina, ME, Italy
- Novartis Investigative Site — Milan, MI, Italy
- Novartis Investigative Site — Padova, PD, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.